OptimizeRx Corp — Director's Dealing 2024

Dec 27, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2024-12-23

Reporting Person: Besch Doug (Chief Product Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-23	Common Stock	A	41408	—	Acquired	52991	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-23	Stock Option	$4.83	A	77742	Acquired	2027-12-23	Common Stock (77742)	Direct

Footnotes

F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on December 23, 2025, which is the first anniversary of the date of grant.

F2: The stock option vests in three equal annual installments beginning December 23, 2025, the first anniversary of the grant date.